Cancer name Glioblastoma Multiforme
Cancer Type GBM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment S3I201
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature Triosephosphate isomerase
Official Symbol TPI1
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Hexokinase-1 (1.89), Phosphoglycerate kinase 1 (1.77), 6-phosphofructokinase type C (2.60), Triosephosphate isomerase (1.54), L-lactate dehydrogenase B chain (1.65) and Phosphoglucomutase-1 (2.04), which are glycolytic enzymes and show increase activity in glial cells, were found with increased expression in response to S3I201 treatment.
PMID 27565396
Title Proteomic level changes associated with S3I201 treated U87 glioma cells